Muhammad Yasir- Rph

22/03/2026

غیر معیاری مضر صحت
# # #

18/03/2026

Ketamine Injection Alert – Important Public Notice
The Drug Testing Laboratories, Punjab, have identified certain batches of Ketamine Injection as requiring attention. The Provincial Quality Control Board has issued a Prompt Alert for the following batches:
Batch GN4775 (Expiry: Dec-2027) – KWALITY Pharmaceuticals Ltd.
Batch 1117S086 (Expiry: Jun-2028) – Genix Pharma (Pvt) Ltd.
Healthcare providers, distributors, and pharmacies are advised to immediately review stock, halt dispensation of affected batches, and ensure medicines are sourced only from authorized outlets. Patients and consumers should verify product authenticity before use.
This post is for awareness. Stay informed, stay safe.

17/03/2026

🚨 Drug Safety Alert – Deka-Duralin Injection

The Drug Testing Laboratories, Punjab has issued a Prompt Alert (Class-I) regarding Deka-Duralin Injection 1 mL (Nandrolone Decanoate 100 mg/mL) after the product was declared spurious under the Drugs Act, 1976.

Batch Details:
Batch No: H-191
Expiry Date: May 2026
Purported Manufacturer: Hansel Pharmaceuticals (Pvt) Ltd., Lahore

According to the regulatory notice, the product was recovered from unregistered premises and classified as spurious under Section 3(zb) of the Drugs Act, 1976. Healthcare professionals, pharmacies, distributors, and medical stores are strongly advised to immediately stop dispensing or distributing this batch and report any available stock to the relevant drug regulatory authorities.

Ensuring patient safety and product authenticity remains a critical priority. Healthcare stakeholders should verify stock, maintain proper distribution records, and comply with recall instructions issued by regulatory authorities.

⚠️ If you encounter this batch in the supply chain, quarantine the product and notify the drug inspector immediately.

17/03/2026

Official Safety Update – Valron-P 50 mg Tablet (Diclofenac Sodium)
According to the Drug Regulatory Authority of Pakistan (DRAP) Recall Alert No. II/S/01-26-131 dated 14 January 2026, a specific batch of Valron-P 50 mg tablets (each containing Diclofenac Sodium) has been declared “Sub-standard” following quality evaluation by Provincial Drug Testing Laboratories. �

Drug Regulatory Authority of Pakistan
📌 Product Details:
• Product Name: Valron-P 50 mg Tablet (Diclofenac Sodium) �

• Batch Number: T-03624 �

• Reason for Classification: Failed Disintegration and Dissolution tests — critical quality parameters that influence drug release and performance. �
Drug Regulatory Authority of Pakistan
Drug Regulatory Authority of Pakistan
Regulatory Actions:

• DRAP and provincial drug control authorities have directed immediate market surveys and recall activities for the affected batch. �
• Distributors, pharmacies, and healthcare facilities are urged to identify, quarantine, and return stock from batch T-03624. �

• Healthcare professionals should monitor supply chains and report quality concerns or adverse events to the National Pharmacovigilance Centre. �

Drug Regulatory Authority of Pakistan

Important Clarification
: This notice applies only to the specific tested batch (T-03624). It does not imply that all Valron-P products are unsafe; it highlights the need for rigorous quality assurance and regulatory compliance. �
Drug Regulatory Authority of Pakistan

Source: Drug Regulatory Authority of Pakistan – Recall Alert (Class-II) for Substandard Products. �

15/03/2026

15/03/2026

غیر معیاری مُضِرصحت انجیکشن۔
مُختاط رہِیں محفوظ رہِیں۔

13/03/2026

13/03/2026

ACEFYL Cough Syrup Recall Alert 🚨

13/03/2026

Pakistani Prescription

13/03/2026

Substandard Medicine Constitutes Fifty Percent of Total Medications in KPK, Report Reveals 🤕💊🚨

23/09/2024

Zodip Amlodipine

20/09/2024

Vitamin C